Log in
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Dynamic quotes 

MarketScreener Homepage  >  Equities  >  Nyse  >  Eli Lilly and Company    LLY


News SummaryMost relevantAll newsPress ReleasesOfficial PublicationsSector news

NCLAT Affirms That The De Minimis Exemption Should Have Always Applied To The "True" Target

share with twitter share with LinkedIn share with facebook
share via e-mail
03/19/2020 | 11:11am EDT

The National Company Law Appellate Tribunal (NCLAT), in its judgment dated 12 March 2020, has set aside the order of the Competition Commission of India (CCI) imposing a penalty of INR 10,000,000 (Indian Rupees Ten million) on Eli Lilly and Company (Eli Lilly) for not notifying the acquisition of Novartis Animal Health business in India (NAH) (a business division of Novartis India Limited) to the CCI or what is popularly known as 'gun jumping'.

The CCI had earlier concluded that Eli Lilly was in contravention of Section 6(2) of the Competition Act, 2002 (Competition Act) for not notifying its acquisition of NAH. As a background, the Central Government had issued a notification dated 4 March 2011 whereby it exempted from merger control notification obligations an "enterprise" that was being acquired and whose value of assets and turnover in India fell below a certain defined threshold (De Minimis Exemption). The CCI held that whether De Minimis Exemption is applicable would not be assessed on the basis of the assets/turnover of the business being acquired i.e., NAH, but on the basis of the assets/turnover of the incorporated entity, i.e., Novartis India Limited.

Eli Lilly contended that the CCI has erroneously applied thresholds of the De Minimis Exemption to the incorporated entity (Novartis India Limited) and not NAH. The Competition Act applies the test of threshold to the "person" or "enterprise" being acquired, and expressly defines "enterprise" broadly to include both incorporated and non-incorporated businesses. Further, the subsequent notification (discussed below) along with the press release issued by the Government of India clarified that the De Minimis Exemption would apply to the business being acquired or the "true" target.

Based on the arguments of Eli Lilly and the CCI, the NCLAT concluded that the CCI had failed to appreciate that the De Minimis Exemption was available to the acquisition of NAH by Eli Lilly. The NCLAT relied on the subsequent de minimis exemption notification of the Central Government dated 27 March 2017 and the press release of Government of India dated 30 March 2017 which clarified the intent of the Government that the exemption should be available to the business being acquired and not merely to incorporated entities.

Agreeing with Eli Lilly's arguments, the NCLAT concurred that for the purpose of the calculation of assets and turnover what is being acquired is relevant as the assets/turnover of what is left over with the sellers after the acquisition will have no role to play in the context of the business conducted by the purchaser post-acquisition.

Interestingly, the NCLAT also made an important observation with regard to the Competition Commission of India (Procedure in Regard to the Transaction of Business Relating to Combinations) Regulations, 2011. The NCLAT held that Section 6(2) of the Competition Act states that "....any person or enterprise, who or which proposes to enter into a combination, shall give notice to the Commission...". Thus, the proposer is obligated to notify to the CCI. However, the delegated legislation states that in case of an acquisition, the obligation to file the notice is with the acquirer, which is contrary to the express statutory provisions and its intent.


KCO represented Eli Lilly before the NCLAT. KCO has been in the forefront in arguing that in cases of asset acquisitions, the De Minimis Exemption was always intended to apply to the "true" target and not to the seller incorporated entity. Unfortunately, many filings were made to the CCI without any competitive significance in the period until the subsequent Government of India notification of March 2017 clarified the position. This NCLAT decision puts to rest any doubt about De Minimis Exemptions (as it existed then) being applicable to the actual target in cases of assets acquisition. The CCI's narrow interpretation of the term "enterprise" has also faced challenges elsewhere. The Hon'ble Supreme Court of India in the decision of CCI v Coordination Committee of Artistes and Technicians of West Bengal Film and Television and Others, (2017) 5 SCC 17 provided clarity about the term "enterprise" under the Competition Act. The Hon'ble Supreme Court ruled that a functional approach should be adopted to interpret "enterprise" where carrying out of an economic activity is central to its definition, regardless of any legal form. It is welcoming that the recently proposed Competition (Amendment) Bill, 2020 has also suggested a broad definition of the term "enterprise" on these lines.

The content of this document do not necessarily reflect the views/position of Khaitan & Co but remain solely those of the author(s). For any further queries or follow up please contact Khaitan & Co at legalalerts@khaitanco.com

Mr Manas Kumar Chaudhuri
Khaitan & Co
One Indiabulls Centre
13th Floor, Tower 1
841 Senapati Bapat Marg
400 013
Tel: 226636 5000
Fax: 226636 5050
E-mail: bdo@khaitanco.com, Nilanjan.ghose@khaitanco.com
URL: www.khaitanco.com

© Mondaq Ltd, 2020 - Tel. +44 (0)20 8544 8300 - http://www.mondaq.com, source Business Briefing

Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY -2.12% 147.96 Delayed Quote.12.58%
NOVARTIS AG -0.63% 81.74 Delayed Quote.-10.47%
NOVARTIS INDIA LIMITED 2.06% 567.1 End-of-day quote.-15.05%
share with twitter share with LinkedIn share with facebook
share via e-mail
05/26ELI LILLY AND : Statement from Lilly Chairman and CEO Dave Ricks on New Part D S..
05/26ELI LILLY AND : Boehringer Ingelheim to Study Diabetes Drug Jardiance After Hear..
05/26ELI LILLY AND : Boehringer Ingelheim and Lilly to collaborate with Duke Clinical..
05/25ELI LILLY AND : AbCellera Announces Multi-Year Antibody Discovery Collaboration ..
05/23ELI LILLY AND : Sheep Farming And The Doctrine Of Equivalents
05/20ELI LILLY AND COMPANY : - Results of GERAS-US Study Demonstrate Societal Cost Bu..
05/19ELI LILLY AND : Results of GERAS-US Study Demonstrate Societal Cost Burden for P..
05/18Chugai enters into a License Agreement for Chugai's Antibody Engineering Tech..
05/15Gilead to end coronavirus drug trials, adding to access worry - researchers
05/14ELI LILLY AND COMPANY : - Lilly Oncology Showcases Innovation in Cancer Research..
More news
Financials (USD)
Sales 2020 23 903 M
EBIT 2020 7 282 M
Net income 2020 5 815 M
Debt 2020 10 130 M
Yield 2020 2,01%
P/E ratio 2020 23,5x
P/E ratio 2021 18,6x
EV / Sales2020 6,03x
EV / Sales2021 5,57x
Capitalization 134 B
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 18
Average target price 158,31 $
Last Close Price 147,96 $
Spread / Highest target 25,7%
Spread / Average Target 7,00%
Spread / Lowest Target -18,9%
EPS Revisions
David A. Ricks Chairman, President & Chief Executive Officer
Joshua L. Smiley Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Aarti S. Shah Chief Information & Digital Officer, Senior VP
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON-0.90%380 857
ROCHE HOLDING AG9.63%302 928
PFIZER, INC.-4.31%208 251
MERCK & CO., INC.-15.05%195 012
NOVARTIS AG-10.47%187 475